210 related articles for article (PubMed ID: 16450317)
1. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain.
Schreiber SA; Russmann A
Exp Clin Endocrinol Diabetes; 2006 Jan; 114(1):41-2. PubMed ID: 16450317
[No Abstract] [Full Text] [Related]
2. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
Spirk D; Lareida J; Scheidegger K; Diem P
Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
[TBL] [Abstract][Full Text] [Related]
3. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.
Schreiber SA; Haak T
Diabetes Obes Metab; 2007 Jan; 9(1):31-8. PubMed ID: 17199716
[TBL] [Abstract][Full Text] [Related]
4. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
[TBL] [Abstract][Full Text] [Related]
6. [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success].
MMW Fortschr Med; 2005 Aug; 147(33-34):44-5. PubMed ID: 16138636
[No Abstract] [Full Text] [Related]
7. Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice.
Schreiber SA; Russmann A
Curr Med Res Opin; 2007 Dec; 23(12):3131-6. PubMed ID: 17988433
[TBL] [Abstract][Full Text] [Related]
8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fasting capillary glucose variability between insulin glargine and NPH.
Mu P; Lu H; Zhang G; Chen Y; Fu J; Wang M; Shu J; Zeng L
Diabetes Res Clin Pract; 2011 Jan; 91(1):e4-7. PubMed ID: 20970870
[TBL] [Abstract][Full Text] [Related]
10. [Start of insulin therapy. How to ensure patient compliance?].
MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
[No Abstract] [Full Text] [Related]
11. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
[TBL] [Abstract][Full Text] [Related]
12. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
[TBL] [Abstract][Full Text] [Related]
14. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
[TBL] [Abstract][Full Text] [Related]
15. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
16. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
17. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
18. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice.
Schreiber SA; Ferlinz K; Haak T
Diabetes Technol Ther; 2008 Apr; 10(2):121-7. PubMed ID: 18260775
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
20. Optimizing glycemic control with insulin glargine.
Williams JB
Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
[No Abstract] [Full Text] [Related]
[Next] [New Search]